An Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn's Disease
Status:
Recruiting
Trial end date:
2026-09-24
Target enrollment:
Participant gender:
Summary
This is a Phase 3, open-label, multicenter extension study to evaluate safety and efficacy of
ozanimod in subjects with moderately to severely active Crohn's Disease.